Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, George Lau et al.|NEJM Evidence|2022Cited by 1.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerDo‐Youn Oh, Juan W. Valle, Myung Ah Lee et al.|NEJM Evidence|2022Cited by 1.1k
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyAmanda Psyrri, Tanguy Y. Seiwert, Jérôme Fayette et al.|Annals of Oncology|2022Cited by 144
The MEK/ERK Pathway Acts Upstream of NFκB1 (p50) Homodimer Activity and Bcl-2 Expression in a Murine B-Cell Lymphoma Cell LineJohn F. Kurland, Raymond E. Meyn|Journal of Biological Chemistry|2003Cited by 69